Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Calcitriol

Criteria

Inclusion Criteria:

• Biopsy-proven Ig AN patients aged 20-70 years

• Patients with residual proteinuria > 500 mg/g creatinine despite renin-angiotensin system blockade and adequate blood pressure control for more than 3 months

• Patients who give informed consent, and 4) estimated GFR >= 30 ml/min/1.73 m2.

Exclusion Criteria:

• patients < 20 years or > 70 years

• hypersensitivity to vitamin D analogs

• patients who need urgent dialysis

• hypercalcemia within 3 months (uncorrected serum calcium level > 10.2 mg/dL)

• clinical features of rapidly progressive glomerulonephritis

• life expectancy less than 24 months

• uncontrolled hypertension

• decompensated liver or lung disease

• symptomatic heart failure (NYHA class II-IV or LVEF < 40%)

• estimated GFR < 30 ml/min/1.73 m2.